CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.
| Revenue (Most Recent Fiscal Year) | $37.31M |
| Net Income (Most Recent Fiscal Year) | $-366.25M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 152.95 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.23 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1218.98% |
| Net Margin (Trailing 12 Months) | -1229.43% |
| Return on Equity (Trailing 12 Months) | -20.05% |
| Return on Assets (Trailing 12 Months) | -17.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 16.61 |
| Quick Ratio (Most Recent Fiscal Quarter) | 16.61 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $22.64 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.29 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.34 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.43 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 90.95M |
| Free Float | 87.04M |
| Market Capitalization | $5.82B |
| Average Volume (Last 20 Days) | 2.58M |
| Beta (Past 60 Months) | 1.84 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.20% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |